Trial # | Type | Study Status | Status Date | Title |
---|
ASCO TAPUR | Advanced Solid Tumors | Open Active | 2021-10-20 | ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR) Study |
INST DARE | Breast Advanced | Open Active | 2021-08-10 | INST DARE: CRITERIUM Inc., Academic Breast Cancer Consortium DARE: A randomized, phase II trial of circulating tumor DNA-guided second line adjuvant therapy for high residual risk, stage II-III, estrogen receptor positive, HER2 negative breast cancer (DARE) |
INST University of Arizona 1807 | Breast Advanced | Open Active | 2020-02-17 | (CLOSED TO IRB) INST University of Arizona 1807: A Randomized Phase II Study to Evaluate Efficacy of T-DM1 with or without Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer |
CCTG MA.39 | Breast Neoadjuvant | Open Active | 2018-08-21 | CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer |
SWOG S1706 | Breast Neoadjuvant | Open Active | 2023-09-08 | SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer |
SWOG S1703 | Breast Other | Open Active | 2020-04-28 | SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer |
SWOG S1912CD | Breast Other | Open Active | 2023-01-18 | SWOG S1912CD: A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery Of A Proactive Financial Navigation Intervention (CREDIT) |
NRG-GI008 | GI Colorectal Adjuvant | Open Active | 2022-08-19 | NRG Oncology NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease |
Alliance A032001 | GU Ureter Advanced | Open Active | 2023-02-20 | Alliance A032001 MAIN-CAV: Phase III Randomized Trial Of Maintenance Cabozantinib And Avelumab Vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy In Patients With Metastatic Urothelial Cancer |
GOG 0263 | GYN Cervical Adjuvant | Open Active | 2011-02-07 | GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy |
ECOG-ACRIN EA3202 | Head And Neck Advanced | Open Active | 2023-12-05 | ECOG-ACRIN EA3202: A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers |
ALLIANCE A211901 | Head And Neck Other | Open Active | 2023-03-31 | ALLIANCE A211901: Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions |
SWOG S1925 | Hematology Chronic Leukemia | Open Active | 2023-02-03 | SWOG S1925: Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study |
SWOG S1803 | Hematology Myeloma | Open Active | 2024-02-29 | SWOG S1803: Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study) |
ECOG-ACRIN NHLBI-MDS | Hematology Other | Open Active | 2020-05-18 | ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History |
Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-04-21 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
ECOG-ACRIN E4512 | Lung NSCLC Adjuvant | Open Active | 2019-03-01 | ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
SWOG LungMAP | Lung NSCLC Advanced | Open Active | 2019-03-26 | SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study) |
DCP-001 | Supportive | Open Active | 2017-05-24 | DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) |
DCP-001A | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
DCP-001B | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
DCP-001C | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
DCP-001D | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
Trial # | Type | Study Status | Status Date | Title |
---|
SWOG S2007 | Breast Advanced | Open Active | 2023-07-20 | SWOG S2007: A Phase II Trial Of Sacituzumab Govitecan (IMMU-132) (NSC #820016) For Patients With HER2-Negative Breast Cancer and Brain Metastases |
INST DARE | Breast Advanced | Open Active | 2021-12-06 | INST DARE: CRITERIUM Inc., Academic Breast Cancer Consortium DARE: A randomized, phase II trial of circulating tumor DNA-guided second line adjuvant therapy for high residual risk, stage II-III, estrogen receptor positive, HER2 negative breast cancer (DARE) |
Alliance A011801 | Breast Adjuvant | Open Active | 2021-05-17 | Alliance A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib |
ASCO TAPUR | Advanced Solid Tumors | Open Active | 2021-10-20 | ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR) Study |
NRG-GU009 | GU Other | Open Active | 2022-10-05 | NRG Oncology NRG-GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT) |
Alliance A021602 | GI Other | Open Active | 2020-12-03 | Alliance A021602: Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET) |
NRG-GI008 | GI Colorectal Adjuvant | Open Active | 2022-08-19 | NRG Oncology NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease |
SWOG S1703 | Breast Other | Open Active | 2020-03-02 | SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer |
S2010 | Breast Other | Open Active | 2023-05-30 | SWOG S2010: A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN) |
GOG 0263 | GYN Cervical Adjuvant | Open Active | 2018-06-07 | GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy |
NRG-GU010 | GU Prostate Neoadjuvant | Open Active | 2024-01-11 | NRG Oncology NRG-GU010: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE) |
ECOG-ACRIN EA6141 | Skin Melanoma Advanced | Open Active | 2023-12-01 | ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma |
SWOG S1925 | Hematology Chronic Leukemia | Open Active | 2023-02-09 | SWOG S1925: Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study |
NRG-GY026 | GYN Endometrial Neoadjuvant | Open Active | 2022-11-22 | NRG-GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-Zzfx (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma |
DCP-001 | Supportive | Open Active | 2023-01-04 | DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) |
Trial # | Type | Study Status | Status Date | Title |
---|
ECOG-ACRIN EAY191 | Advanced Solid Tumors | Open Active | 2023-08-21 | ECOG-ACRIN EAY191: Molecular Analysis for Combination Therapy Choice (ComboMATCH) |
ASCO TAPUR | Advanced Solid Tumors | Open Active | 2021-10-20 | ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR) Study |
NRG Oncology NRG-BN003 | Brain Other | Open Active | 2017-10-20 | NRG Oncology NRG-BN003: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma |
Alliance A071401 | Brain Advanced | Open Active | 2022-01-14 | Alliance A071401: Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations |
ECOG-ACRIN EA1183 | Breast Advanced | Open Active | 2020-10-19 | ECOG-ACRIN EA1183: FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE |
INST UNM 2004 | Breast Adjuvant | Open Active | 2022-05-27 | INST UNM 2004: Patient Understanding of the Benefit of Adjuvant Endocrine Therapy in Breast Cancer |
Alliance A011801 | Breast Adjuvant | Open Active | 2021-05-17 | Alliance A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib |
CCTG MA.39 | Breast Neoadjuvant | Open Active | 2018-09-05 | CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer |
SWOG S2007 | Breast Advanced | Open Active | 2021-09-20 | SWOG S2007: A Phase II Trial Of Sacituzumab Govitecan (IMMU-132) (NSC #820016) For Patients With HER2-Negative Breast Cancer and Brain Metastases |
INST DARE | Breast Advanced | Open Active | 2021-08-09 | INST DARE: CRITERIUM Inc., Academic Breast Cancer Consortium DARE: A randomized, phase II trial of circulating tumor DNA-guided second line adjuvant therapy for high residual risk, stage II-III, estrogen receptor positive, HER2 negative breast cancer (DARE) |
SWOG S1706 | Breast Neoadjuvant | Open Active | 2023-09-08 | SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer |
NRG-BR007 | Breast Neoadjuvant | Open Active | 2021-10-29 | NRG Oncology NRG-BR007: A Phase III Clinical Trial evaluating de-escalation of Breast Radiation for conservative treatment of Stage I, hormone sensitive, HER2-Negative, Oncotype recurrence score = 18 Breast Cancer |
ECOG-ACRIN EA1151 | Breast Other | Open Active | 2022-09-29 | ECOG-ACRIN EA1151: Tomosynthesis Mammography Imaging Screening Trial (TMIST) |
ECOG-ACRIN EA1151 | Breast Other | Open Active | 2018-08-31 | ECOG-ACRIN EA1151: Tomosynthesis Mammography Imaging Screening Trial (TMIST) |
SWOG S1912CD | Breast Other | Open Active | 2023-01-18 | SWOG S1912CD: A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery Of A Proactive Financial Navigation Intervention (CREDIT) |
SWOG S1703 | Breast Other | Open Active | 2020-03-02 | SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer |
S2010 | Breast Other | Open Active | 2023-05-30 | SWOG S2010: A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN) |
CIBMTR Protocol for a Research Database | Epidemiological | Open Active | 2020-11-10 | CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries |
CIBMTR Protocol for a Research Database | Epidemiological | Open Active | 2017-06-29 | CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries |
NRG-GI008 | GI Colorectal Adjuvant | Open Active | 2022-08-18 | NRG Oncology NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease |
UNM TCCP | Epidemiological | Open Active | 2017-12-08 | INST UNM 1521: Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer |
UNM 1803 | Epidemiological | Open Active | 2018-06-26 | INST UNM 1803: Enhancing Cancer Prevention and Control Pathways in the Zuni Pueblo-Native Health Initiative |
NRG Oncology/SWOG NRG-GI004/SWOG-S1610 | GI Colorectal Advanced | Open Active | 2023-11-30 | NRG Oncology/SWOG NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer |
Alliance A022101 | GI Colorectal Advanced | Open Active | 2023-07-11 | Alliance A022101: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients With Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur) |
Alliance A022102 | GI Esophageal Advanced | Open Active | 2023-10-12 | Alliance A022102: Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma |
INST UNM 1809 | GI Colorectal Prevention | Open Active | 2018-12-27 | INST UNM 1809: Dissemination of a Colorectal Cancer Screening Program Across American Indian Communities in the Southern Plains & Southwest United States |
UNM 1603 | GI Other | Open Active | 2016-11-30 | INST UNM 1603: Enhancing Prevention Pathways Toward Tribal Colorectal Health |
Alliance A022104 | GI Other | Open Active | 2024-01-18 | Alliance A022104: The Janus Rectal Cancer Trial: A Randomized Phase II/III Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy Regarding Clinical Complete Response and Disease-Free Survival in Patients with Locally Advanced Rectal Cancer |
ECOG-ACRIN EA2197 | GI Gastric Adjuvant | Open Active | 2021-05-28 | ECOG-ACRIN EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial |
SWOG S2104 | GI Pancreatic Adjuvant | Open Active | 2022-03-21 | SWOG S2104: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumor |
ECOG-ACRIN EA2192 | GI Pancreatic Adjuvant | Open Active | 2023-09-13 | ECOG-ACRIN EA2192: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation |
Alliance A021806 | GI Pancreatic Adjuvant | Open Active | 2020-12-08 | Alliance A021806: A Phase III Trial Of Perioperative Versus Adjuvant Chemotherapy For Resectable Pancreatic Cancer |
NRG-GU009 | GU Other | Open Active | 2022-04-15 | NRG Oncology NRG-GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT) |
EA8212 | GU Other | Open Active | 2023-08-07 | ECOG-ACRIN EA8212: A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Nave High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE) |
UNM 1805 | GU Other | Open Active | 2019-01-08 | INST UNM 1805: Trait Mindfulness in Distressed New Mexico Prostate Cancer Survivors |
NRG-GU011 | GU Other | Open Active | 2022-08-08 | NRG Oncology NRG-GU011: A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean) |
SWOG S1931 | GU RenalCell Adjuvant | Open Active | 2023-10-11 | SWOG S1931: Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial) |
Alliance A031704 | GU Renal Cell Advanced | Open Active | 2023-10-13 | Alliance A031704: PD-inhibitor (nivolumab) and Ipilimumab followed by nivolumab vs. VEGF TKI cabozantinib with nivolumab: a phase III trial in metastatic untreated REnal cell cancEr (PDIGREE) |
NRG-GU010 | GU Prostate Neoadjuvant | Open Active | 2022-03-29 | NRG Oncology NRG-GU010: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE) |
NRG Oncology NRG-GY006 | GYN Cervical Advanced | Open Active | 2021-08-31 | NRG Oncology NRG-GY006: A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer |
GOG-3043 | GYN Cervical Adjuvant | Open Active | 2022-06-29 | GOG Foundation, Inc. GOG-3043: A Randomized Controlled Trial of Robotic Versus Open Radical Hysterectomy for Cervical Cancer (ROCC) |
NRG-GY028 | GYN Endometrial Advanced | Open Active | 2023-05-04 | NRG Oncology NRG-GY028: A Phase IB and Randomized Phase II Trial of Megestrol Acetate With or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer |
NRG EAY191-N4 | GYN Endometrial Advanced | Open Active | 2023-08-21 | NRG EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial |
NRG-GY025 | GYN Endometrial Adjuvant | Open Active | 2023-10-13 | NRG Oncology NRG-GY025: A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma |
UNM 1509 | GYN Other | Open Active | 2020-06-29 | INST UNM 1509: Single Institution (UNM) Prospective Laboratory Study of Cancer and Immune Cells in the Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies |
NRG-GY026 | GYN Endometrial Neoadjuvant | Open Active | 2024-04-12 | NRG-GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-Zzfx (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma |
ECOG-ACRIN EA3191 | Head And Neck Advanced | Open Active | 2023-06-13 | ECOG-ACRIN EA3191: A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features |
ECOG-ACRIN EA3161 | Head And Neck Advanced | Open Active | 2023-10-13 | ECOG-ACRIN EA3161: A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC |
NRG-HN009 | Head And Neck Advanced | Open Active | 2022-03-21 | NRG-Oncology NRG-HN009: Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
INST 1310 | Head And Neck Advanced | Open Active | 2015-02-25 | INST 1310: An Observational, Single-Institution Pilot/Feasibility Study of Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma |
ECOG-ACRIN EA3202 | Head And Neck Advanced | Open Active | 2023-12-05 | ECOG-ACRIN EA3202: A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers |
ALLIANCE A211901 | Head And Neck Other | Open Active | 2023-03-31 | ALLIANCE A211901: Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions |
RTOG 1216 | Head And Neck Advanced | Open Active | 2023-11-29 | RTOG 1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck |
SWOG S1905 | Hematology Acute Leukemia | Open Active | 2023-12-19 | SWOG S1905: A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T- Cell Lymphoblastic Lymphoma (T-LBL) |
EA9152 | Hematology Acute Leukemia | Open Active | 2023-06-09 | ECOG-ACRIN EA9152: A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia |
SWOG S1712 | Hematology Chronic Leukemia | Open Active | 2019-02-21 | SWOG S1712: A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease |
UNM 1512 | Hematology Acute Leukemia | Open Active | 2018-05-23 | INST UNM 1512: A New Drug Discovery Platform using High Throughput Flow Cytometry and a PDX Tissue Repository in AML and MDS |
SWOG S2114 | Hematology Lymphoma Non-Hodgkins | Open Active | 2024-04-09 | SWOG S2114: A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment For Relapsed/Refractory Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma |
Pharm EZH-302 | Hematology Lymphoma Non-Hodgkins | Open Active | 2022-06-21 | Epizyme EZH-302: A Phase 1b/3 Double-blind, Randomized, Active-controlled, 3-stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma |
SWOG S1925 | Hematology Chronic Leukemia | Open Active | 2023-02-03 | SWOG S1925: Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study |
ECOG-ACRIN NHLBI-MDS | Hematology Other | Open Active | 2020-05-18 | ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History |
SWOG S1803 | Hematology Myeloma | Open Active | 2023-12-08 | SWOG S1803: Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study) |
ECOG ACRIN EAA181 | Hematology Myeloma | Open Active | 2021-12-17 | ECOG ACRIN EAA181: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation |
INST UNM 2105 | Ill Defined | Open Active | 2021-02-05 | INST UNM 2105: Post-Traumatic Stress Disorder in Myeloma and Non-Hodgkins Lymphoma in New Mexico |
INST UNM 1903 | Hematology Other | Open Active | 2021-06-25 | INST UNM 1903: Collection of Apheresed Leukocytes for Research and Cell Therapy Process Development |
ECOG-ACRIN EA5182 | Lung NSCLC Advanced | Open Active | 2023-05-03 | ECOG-ACRIN EA5182: Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) |
ECOG-ACRIN E4512 | Lung NSCLC Adjuvant | Open Active | 2019-03-19 | ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-05-09 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
SWOG S2302 | Lung NSCLC Advanced | Open Active | 2023-08-04 | SWOG S2302: Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer |
SWOG S1914 | Lung NSCLC Advanced | Open Active | 2023-11-30 | SWOG S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC |
SWOG LungMAP | Lung NSCLC Advanced | Open Active | 2019-03-14 | SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study) |
SWOG S1823 | Solid Tumors Other | Open Active | 2021-03-26 | SWOG S1823: A Prospective Observational Cohort Study To Assess Mirna 371 For Outcome Prediction In Patients With Newly Diagnosed Germ Cell Tumors |
Alliance A081801 | Lung SCLC Adjuvant | Open Active | 2022-03-15 | Alliance A081801: Integration Of Immunotherapy Into Adjuvant Therapy For Resected NSCLC: ALCHEMIST Chemo-IO |
DCP-001A | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
DCP-001 | Supportive | Open Active | 2016-08-17 | DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) |
SWOG S2101 | Solid Tumors Other | Open Active | 2024-02-14 | SWOG S2101: Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study |
DCP-001C | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
DCP-001B | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
SWOG S2205 | Supportive | Open Active | 2023-09-26 | SWOG S2205: ICE COMPRESS: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Included Peripheral Neuropathy |
DCP-001D | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |